Search

Your search keyword '"Nikolic, Tatjana"' showing total 9 results
Start Over Author "Nikolic, Tatjana" Database OpenAIRE
Sorry, I don't understand your search. ×
9 results on '"Nikolic, Tatjana"'

1. Philosophieren mit Kindern: Projektbericht

Author

Krnjic, Slavica, Nikolic, Tatjana, Pfyffer, Nadine, and Yücel, Yesim Melissa

Abstract

Im Rahmen dieses Projektes haben vier Studierende der Sozialen Arbeit an der Hochschule Luzern ihre Idee eines Lehrmittels zum Philosophieren mit Kindern der ersten und zweiten Primarschulklasse umgesetzt; entstanden sind einerseits Anleitungen für nicht philosophiedidaktisch ausgebildete Lehrpersonen, andererseits auch für Bezugspersonen zum Philosophieren zu Hause. Ebenfalls erarbeitet wurde das Lehrmittel, bestehend aus situativ verwendbaren Sequenzen. Die erarbeiteten Produkte wurden der Auftraggeberin, einer Lehrperson der Volksschule St. Karli, zum regelmässigen Gebrauch übergeben. Das Lehrmittel verfügt über Anleitungen zu einer prozessorientierten und ergebnisoffenen, philosophischen Gesprächsführung. Angelehnt an Wissen aus der Philosophie sowie bereits bestehenden Lehrmitteln entstand ein Produkt, welches professionelles, theoretisches Wissen aus der Sozialen Arbeit mit neuen, kritisch reflektierten pädagogischen Haltungen verbindet, um die Förderung der sozialen, emotionalen, personalen und metakognitiven Fähigkeiten von Schüler:innen zu fördern. Gestützt wird das Vorhaben durch zahlreiche Studien über den Nutzen und die Erfolge des philosophischen Gesprächs im Kontext von Grundschulklassen und durch die partizipative Erarbeitung einiger Elemente des interaktiven Methodenkoffers mit der Lehrperson sowie den Kindern wird die Nachhaltigkeit des Projekts angestrebt., + Code Diss LU: hslusa pasa be + Code Diss LU: hslusa pasp be + Fussnote: Projekt-Arbeit, Hochschule Luzern – Soziale Arbeit, Studienrichtung Sozialarbeit & Sozialpädagogik, 2022 + NL-Code: NLLUHSA202211

Published
2022
Full Text
View/download PDF

2. What does cell therapy manufacturing cost?: a framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings

Author

Ten Ham, Renske M T, Hövels, Anke M, Hoekman, Jarno, Frederix, Geert W J, Leufkens, Hubert G M, Klungel, Olaf H, Jedema, Inge, Veld, Sabrina A J, Nikolic, Tatjana, Van Pel, Melissa, Zwaginga, Jaap J, Lin, Fong, de Goede, Anna L, Schreibelt, Gerty, Budde, Sandy, de Vries, I Jolanda M, Wilkie, Gwen M, Dolstra, Harry, Ovelgönne, Hans, Meij, Pauline, Mountford, Joanne C, Turner, Marc L, Hoefnagel, Marcel H N, Innovation Studies, Afd Pharmacoepi & Clinical Pharmacology, Innovation and Sustainability, Sub Pharmacotherapy, Theoretical, Pharmacoepidemiology, Pharmacoepidemiology and Clinical Pharmacology, Innovation Studies, Afd Pharmacoepi & Clinical Pharmacology, Innovation and Sustainability, Sub Pharmacotherapy, Theoretical, Pharmacoepidemiology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
0301 basic medicine, Cancer Research, Cost estimate, Computer science, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Best practice, Supply chain, Immunology, Cell- and Tissue-Based Therapy, 03 medical and health sciences, 0302 clinical medicine, cell and gene therapies, Humans, Immunology and Allergy, Operations management, Activity-based costing, Genetics (clinical), cell-based therapies, Transplantation, cost framework, Academies and Institutes, Commerce, advanced therapy medicinal products, Cell Biology, cost methodology, Manufacturing cost, Europe, Product (business), manufacturing cost, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], 030104 developmental biology, Oncology, Cost driver, 030220 oncology & carcinogenesis, Scale (social sciences), Costs and Cost Analysis, Health Facilities
Abstract

Contains fulltext : 220591.pdf (Publisher’s version ) (Open Access) BACKGROUND AIMS: Recent technical and clinical advances with cell-based therapies (CBTs) hold great promise in the treatment of patients with rare diseases and those with high unmet medical need. Currently the majority of CBTs are developed and manufactured in specialized academic facilities. Due to small scale, unique characteristics and specific supply chain, CBT manufacturing is considered costly compared to more conventional medicinal products. As a result, biomedical researchers and clinicians are increasingly faced with cost considerations in CBT development. The objective of this research was to develop a costing framework and methodology for academic and other small-scale facilities that manufacture cell-based therapies. METHODS: We conducted an international multi-center costing study in four facilities in Europe using eight CBTs as case studies. This study includes costs from cell or tissue procurement to release of final product for clinical use. First, via interviews with research scientists, clinicians, biomedical scientists, pharmacists and technicians, we designed a high-level costing framework. Next, we developed a more detailed uniform methodology to allocate cost items. Costs were divided into steps (tissue procurement, manufacturing and fill-finish). The steps were each subdivided into cost categories (materials, equipment, personnel and facility), and each category was broken down into facility running (fixed) costs and operational (variable) costs. The methodology was tested via the case studies and validated in developer interviews. Costs are expressed in 2018 euros (€). RESULTS: The framework and methodology were applicable across facilities and proved sensitive to differences in product and facility characteristics. Case study cost estimates ranged between €23 033 and €190 799 Euros per batch, with batch yield varying between 1 and 88 doses. The cost estimations revealed hidden costs to developers and provided insights into cost drivers to help design manufacturing best practices. CONCLUSIONS: This framework and methodology provide step-by-step guidance to estimate manufacturing costs specifically for cell-based therapies manufactured in academic and other small-scale enterprises. The framework and methodology can be used to inform and plan cost-conscious strategies for CBTs. 01 juli 2020

Published
2020

4. Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies

Author

Lord, Phillip, Aguillon, Juan C, Anderson, Amy E, Appel, Silke, Benitez-Ribas, Daniel, Ten Brinke, Anja, Broere, Femke, Cools, Nathalie, Cuturi, Maria Cristina, Diboll, Julie, Geissler, Edward K, Giannoukakis, Nick, Gregori, Silvia, van Ham, S Marieke, Lattimer, Staci, Marshall, Lindsay, Harry, Rachel A, Hutchinson, James A, Isaacs, John D, Joosten, Irma, van Kooten, Cees, Lopez Diaz de Cerio, Ascension, Nikolic, Tatjana, Oral, Haluk Barbaros, Sofronic-Milosavljevic, Ljiljana, Ritter, Thomas, Riquelme, Paloma, Thomson, Angus W, Trucco, Massimo, Vives-Pi, Marta, Martinez-Caceres, Eva M, Hilkens, Catharien M U, LS Immunologie, dI&I RA-I&I I&I, School of Computing Science [Newcastle], Newcastle University [Newcastle], Institute of Cellular Medicine [Newcastle], Instituto de Ciencias Biomédicas [Santiago, Chile] (Facultad de Medicina), Broegelmann Research Laboratory [Bergen, Norway] (Department of Clinical Science), University of Bergen (UiB), Department of Immunology [Barcelona, Spain], Hospital Clinic i Provincial de Barcelona (SCReN)-Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas [Barcelona, Spain] (CIBERehd), Department of Immunopathology [Amsterdam, The Netherlands], University of Amsterdam [Amsterdam] (UvA), Department of Infectious Diseases and Immunology [Utrecht, The Netherlands], Utrecht University [Utrecht]-WHO Collaborating Center for Campylobacter /OIE Reference Laboratory for Campylobacteriosis (Utrecht), Laboratory of Experimental Hematology [Wilrijk, Belgium] (Faculty of Medicine and Health Sciences), University of Antwerp (UA)-Vaccine & Infectious Disease Institute [Wilrijk, Belgium] (VAXINFECTIO), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Institut de transplantation urologie-néphrologie (ITUN), Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Department of Surgery, Section of Experimental Surgery [Regensburg, Germany], University Hospital Regensburg, Institute of Cellular Therapeutics [Pittsburgh, PA, USA], Allegheny Health Network, Division of Regenerative Medicine, Stem Cells and Gene Therapy [Milan, Italy], IRCCS Ospedale San Raffaele [Milan, Italy]-S. Raffaele Scientific Institute-San Raffaele Telethon Institute for Gene Therapy [Milan, Italy] (SR-Tiget), Department of Laboratory Medicine [Nijmegen, the Netherlands], Radboud Proteomics Centre [Nijmegen, the Netherlands], Department of Nephrology [Leiden, The Netherlands], Leiden University Medical Center (LUMC), Area of Cell Therapy [Pamplona, Spain], University Clinic of Navarra - CUN [Pamplona, Spain], Department of Immunohematology and Blood Transfusion [Leiden, The Netherlands], Department of Immunology [Bursa, Turkey] (Faculty of Medicine), Uludağ Üniversitesi = Uludag University, Institute for the Application of Nuclear Energy [Belgrade, Serbia] (INEP), University of Belgrade [Belgrade], Regenerative Medicine Institute [Galway, Ireland], National University of Ireland [Galway] (NUI Galway), Thomas E. Starzl Transplantation Institute [Pittsburgh, PA, USA], University of Pittsburgh School of Medicine, Pennsylvania Commonwealth System of Higher Education (PCSHE)-Pennsylvania Commonwealth System of Higher Education (PCSHE), Immunology Division [Badalona, Spain], Health Sciences Research Institute [Badalona, Spain]-Germans Trias i Pujol University Hospital [Badalona, Spain], CIBER of Diabetes and Associated Metabolic Diseases [Madrid, Spain] (CIBERDEM), Instituto de Salud Carlos III [Madrid] (ISC), Department of Cellular Biology, Physiology and Immunology [Barcelona, Spain], Autonomous University of Barcelona, A grant from the European Cooperation in Science and Technology (COST) for the AFACTT project (Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies, BM1305). COST is part of the EU Framework Programme Horizon 2020., ~, LS Immunologie, dI&I RA-I&I I&I, Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı., Oral, Haluk Barbaros, K-7285-2012, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas [Barcelona, Spain] (CIBERehd)-Hospital Clinic i Provincial de Barcelona (SCReN), San Raffaele Telethon Institute for Gene Therapy [Milan, Italy] (SR-Tiget)-IRCCS Ospedale San Raffaele [Milan, Italy]-S. Raffaele Scientific Institute, Germans Trias i Pujol University Hospital [Badalona, Spain]-Health Sciences Research Institute [Badalona, Spain], Germans Trias i Pujol University Hospital [Badalona, Barcelona, Spain] (GTPUH)-Health Sciences Research Institute [Badalona, Spain], Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Universitat Autònoma de Barcelona (UAB), and Le Bihan, Sylvie

Subjects
0301 basic medicine, Science & technology - other topics, Macrophage, 610 Medizin, lcsh:Medicine, Celltherapy, Dendritic cells, Computational Science, Cell therapy, 0302 clinical medicine, Autoimmune disease, Prevalence, Tolerogenicdendriticcells, Medicine, Disease, Antigen-presentingcells, Regulatorymacrophages, ddc:610, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Antigen presenting cell, General Neuroscience, Tolerogenic dendritic cells, Gold standard, General Medicine, 3. Good health, Program sustainability, General Agricultural and Biological Sciences, Engineering sciences. Technology, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], Dendritic cell, Human, Translational Medicine, Minimuminformationmodel, Immunology, Antigen-presenting cells, Computational biology, Multidisciplinary sciences, Article, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Clinical Trials, Immune response, Minimum information model, Antigen-presenting cell, Transplantation, business.industry, lcsh:R, Translational medicine, Reporting guidelines, Regulatory macrophages, 030104 developmental biology, business, Tolerogenic antigen resenting cell, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Dendritic Cells, Mixed Lymphocyte Culture Test, Regulatory T Lymphocyte, Model, 030215 immunology
Abstract

Cellular therapies, with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC field to generate a minimum information model for tolAPC (MITAP), providing a reporting framework that will make differences and similarities between tolAPC products transparent. In this way, MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application. This work was supported by a grant from the European Cooperation in Science and Technology (COST) for the AFACTT project (Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies; BM1305). COST is part of the EU Framework Programme Horizon 2020. peer-reviewed

Published
2016
Full Text
View/download PDF

8. Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies

Author

Lord, Phillip, Spiering, Rachel, Aguillon, Juan C., Anderson, Amy E., Appel, Silke, Benitez-Ribas, Daniel, ten Brinke, Anja, Broere, Femke, Cools, Nathalie, Cuturi, Maria Cristina, Diboll, Julie, Geissler, Edward K., Giannoukakis, Nick, Gregori, Silvia, van Ham, S. Marieke, Lattimer, Staci, Marshall, Lindsay, Harry, Rachel A., Hutchinson, James A., Isaacs, John D., Joosten, Irma, van Kooten, Cees, Lopez Diaz de Cerio, Ascension, Nikolic, Tatjana, Oral, Haluk Barbaros, Sofronic-Milosavljevic, Ljiljana, Ritter, Thomas, Riquelme, Paloma, Thomson, Angus W., Trucco, Massimo, Vives-Pi, Marta, Martinez-Caceres, Eva M., and Hilkens, Catharien M. U.

Subjects
610 Medizin, DENDRITIC CELLS, DISEASE, Cell therapy, Minimum information model, Antigen-presenting cells, Autoimmune disease, Transplantation, Tolerogenic dendritic cells, Regulatory macrophages, Reporting guidelines, 3. Good health
Abstract

Cellular therapies, with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC field to generate a minimum information model for tolAPC (MITAP), providing a reporting framework that will make differences and similarities between tolAPC products transparent. In this way, MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.

9. Antropological measurement of the sacroiliac joint

Author

Nikola Krmek, Jo-Osvatic, Ana, Nikolic, Tatjana, Krmek, Vlado, and Salamon, Anton

Subjects
Adult, Anthropometry, Humans, facies auricularis, sacroiliac joint, pelvic bone, os coxae, Sacroiliac Joint, Aged
Abstract

This study was done on 65 isolated pelvic bones, These cadavers belonged to adult people of mature and old age, and they had no pathological changes. These measurements were performed on osteological collection of Department of Anatomy Drago Perović. Many geometrical parameters of facies auricularis were measured, which we considered important for further studies, simulations of joint's action, transfer calculations of the forces from spine to hip joint. We used paper, which partially adapted to the surface of facies auricularis, so the values are closer to real ones than projection values. The results have shown that the average surface of facies auricularis is 13.46 cm(2). There was no statistical significance found between left and right cadavers. For easier orientation we divided surface of facies auricularis into two parts: vertical and horizontal. Height of the vertical part was 3.99 cm, while the width was 2.05 cm. Height of horizontal part was 2.07 cm and the width 3.62 cm.

Catalog

Books, media, physical & digital resources
See catalog results